V
The startup develops an oral medication specifically for treating hereditary hemorrhagic telangiectasia (HHT), a rare disease characterized by vascular malformations. This treatment alleviates symptoms and decreases the formation of new lesions, enabling healthcare providers to manage disease progression effectively.
Basel, Switzerland
Updated 2 months ago
Funding
Funding not disclosed
Funding rounds are not available yet.
Founders
Founder details are not available yet.
Product
Features
- The startup develops an oral medication specifically for treating hereditary hemorrhagic telangiectasia (HHT), a rare disease characterized by vascular malformations. This treatment alleviates symptoms and decreases the formation of new lesions, enabling healthcare providers to manage disease progression effectively.